Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vardenafil Add-on to Inhaled Iloprost in PAH
NCT01649739Phase 4Unknown
- Sponsor
- Rabin Medical Center
- Start
- Sep 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vardenafil in pulmonary arterial hypertension (PAH), sponsored by Rabin Medical Center. Primary endpoints: Change in 6 minute walk distance at 14 weeks and Change in New York Heart Association functional class at 14 weeks. Status: unknown.
02
Drugs
vardenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT01649739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01649739.